(2006). Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clinical Cancer Research
(2002). Angiogenesis and the unique nature of tumor matrix. Molecular Biotechnology
(2001). Angiogenesis in B-cell chronic lymphocytic leukemia: methods of study, clinical significance and prognostic implications. Leukemia and Lymphoma
(2004). Boucher DM: Functions of MAP Kinases: Insights from GeneTargeting Studies.
(2003). Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Molecular Cancer Therapeutics
(2002). DF: B-CLL cells are capable of synthesis and secretion of both pro-and anti-angiogenic molecules. Leukemia
(2009). Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression.
(2006). Goppelt-Struebe M: STAT3-independent inhibition of lysophosphatidic acid-mediated upregulation of connective tissue growth factor (CTGF) by cucurbitacin I. Biochemical Pharmacology
(2008). Hicklin DJ: VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Reviews Cancer
(1999). Rat embryo fibroblasts transformed by c-Jun display highly metastatic and angiogenic activities in vivo and deregulate gene expression of both angiogenic and antiangiogenic factors. Cell Growth and Differentiation
(2000). RK: Angiogenesis in cancer and other diseases. Nature
(2010). SB: Inhibition of constitutive activation of STAT3 by curcurbitacin-I (JSI-124) sensitized human B-leukemia cells to apoptosis. Molecular Cancer Therapeutics
(2008). SB: Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies. Cell Signaling
(2008). SB: Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC.
(2009). SB: Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression. Leukemia and Lymphoma
(2003). Sebti SM: Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Research
(1999). Serine phosphorylation and negative regulation of
(2000). Signal transduction by the JNK group of MAP kinases. Cell
(2000). STAT signaling in the pathogenesis and treatment of leukemias. Oncogene
(1997). STAT3 serine phosphorylation by ERK-dependent and-independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol
(1998). Stress-activated kinases regulate protein stability. Oncogene
(2005). SX: Cucurbitacins and cucurbitane glycosides: structures and biological activities. Natural Product Reports
(2008). Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model. Immunology and Cell Biology
(2010). Thoennissen NH: Cucurbitacin: ancient compound shedding new light on cancer treatment. Scientific World Journal
(2005). Tweardy DJ: Targeting Stat3 in cancer therapy. Anticancer Drugs
(2005). Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1.
(2005). VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist
(2011). Wong AJ: The role of the c-Jun N-terminal kinase 2-α-isoform in non-small cell lung carcinoma tumorigenesis. Oncogene